MEDICLIN AG (MED.DE) Stock Fundamental Analysis
FRA:MED - Deutsche Boerse Ag - DE0006595101 - Common Stock - Currency: EUR
Overall MED gets a fundamental rating of 5 out of 10. We evaluated MED against 25 industry peers in the Health Care Providers & Services industry. There are concerns on the financial health of MED while its profitability can be described as average. A decent growth rate in combination with a cheap valuation! Better keep an eye on MED.
1. Profitability
1.1 Basic Checks
MED had positive earnings in the past year.
MED had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: MED reported negative net income in multiple years.
In the past 5 years MED always reported a positive cash flow from operatings.
1.2 Ratios
MED has a Return On Assets (2.74%) which is in line with its industry peers.
Looking at the Return On Equity, with a value of 11.16%, MED is in the better half of the industry, outperforming 64.00% of the companies in the same industry.
MED has a Return On Invested Capital (5.61%) which is in line with its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for MED is below the industry average of 6.33%.
The 3 year average ROIC (3.46%) for MED is below the current ROIC(5.61%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.74% | ||
| ROE | 11.16% | ||
| ROIC | 5.61% |
ROA(3y)0.85%
ROA(5y)0.34%
ROE(3y)3.39%
ROE(5y)1.18%
ROIC(3y)3.46%
ROIC(5y)2.35%
1.3 Margins
Looking at the Profit Margin, with a value of 3.25%, MED is in line with its industry, outperforming 60.00% of the companies in the same industry.
MED's Profit Margin has improved in the last couple of years.
MED's Operating Margin of 6.99% is in line compared to the rest of the industry. MED outperforms 56.00% of its industry peers.
In the last couple of years the Operating Margin of MED has grown nicely.
MED has a better Gross Margin (83.13%) than 84.00% of its industry peers.
MED's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.99% | ||
| PM (TTM) | 3.25% | ||
| GM | 83.13% |
OM growth 3Y67.11%
OM growth 5Y19.19%
PM growth 3Y148.06%
PM growth 5Y18.19%
GM growth 3Y0.37%
GM growth 5Y0.18%
2. Health
2.1 Basic Checks
MED has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for MED remains at a similar level compared to 1 year ago.
The number of shares outstanding for MED remains at a similar level compared to 5 years ago.
The debt/assets ratio for MED has been reduced compared to a year ago.
2.2 Solvency
MED has an Altman-Z score of 1.60. This is a bad value and indicates that MED is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.60, MED is in line with its industry, outperforming 52.00% of the companies in the same industry.
The Debt to FCF ratio of MED is 12.94, which is on the high side as it means it would take MED, 12.94 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 12.94, MED is doing worse than 60.00% of the companies in the same industry.
MED has a Debt/Equity ratio of 1.96. This is a high value indicating a heavy dependency on external financing.
MED has a Debt to Equity ratio of 1.96. This is in the lower half of the industry: MED underperforms 68.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.96 | ||
| Debt/FCF | 12.94 | ||
| Altman-Z | 1.6 |
ROIC/WACC1.16
WACC4.85%
2.3 Liquidity
A Current Ratio of 1.79 indicates that MED should not have too much problems paying its short term obligations.
The Current ratio of MED (1.79) is better than 80.00% of its industry peers.
MED has a Quick Ratio of 1.75. This is a normal value and indicates that MED is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of MED (1.75) is better than 88.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.79 | ||
| Quick Ratio | 1.75 |
3. Growth
3.1 Past
MED shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 330.51%, which is quite impressive.
Measured over the past years, MED shows a very strong growth in Earnings Per Share. The EPS has been growing by 20.79% on average per year.
The Revenue has decreased by -0.22% in the past year.
Measured over the past years, MED shows a small growth in Revenue. The Revenue has been growing by 2.19% on average per year.
EPS 1Y (TTM)330.51%
EPS 3Y157.01%
EPS 5Y20.79%
EPS Q2Q%138.17%
Revenue 1Y (TTM)-0.22%
Revenue growth 3Y3.65%
Revenue growth 5Y2.19%
Sales Q2Q%-3.05%
3.2 Future
The Earnings Per Share is expected to grow by 6.48% on average over the next years.
Based on estimates for the next years, MED will show a small growth in Revenue. The Revenue will grow by 2.80% on average per year.
EPS Next Y20.73%
EPS Next 2Y12.62%
EPS Next 3Y6.48%
EPS Next 5YN/A
Revenue Next Year4.55%
Revenue Next 2Y2.95%
Revenue Next 3Y2.8%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
MED is valuated cheaply with a Price/Earnings ratio of 5.50.
92.00% of the companies in the same industry are more expensive than MED, based on the Price/Earnings ratio.
MED's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.17.
MED is valuated cheaply with a Price/Forward Earnings ratio of 5.72.
Based on the Price/Forward Earnings ratio, MED is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 22.10. MED is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.5 | ||
| Fwd PE | 5.72 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, MED is valued cheaply inside the industry as 92.00% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, MED is valued a bit cheaper than 80.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.79 | ||
| EV/EBITDA | 3.49 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
MED has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)0.27
PEG (5Y)0.26
EPS Next 2Y12.62%
EPS Next 3Y6.48%
5. Dividend
5.1 Amount
MED has a Yearly Dividend Yield of 1.36%. Purely for dividend investing, there may be better candidates out there.
Compared to an average industry Dividend Yield of 2.77, MED has a dividend in line with its industry peers.
With a Dividend Yield of 1.36, MED pays less dividend than the S&P500 average, which is at 2.40.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.36% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DP0%
EPS Next 2Y12.62%
EPS Next 3Y6.48%
FRA:MED (5/27/2025, 7:00:00 PM)
2.86
-0.08 (-2.72%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners2.09%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap135.85M
Analysts83.33
Price Target4.79 (67.48%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.36% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.44%
PT rev (3m)9.94%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)26.92%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.81%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.5 | ||
| Fwd PE | 5.72 | ||
| P/S | 0.18 | ||
| P/FCF | 3.79 | ||
| P/OCF | 1.69 | ||
| P/B | 0.61 | ||
| P/tB | 0.69 | ||
| EV/EBITDA | 3.49 |
EPS(TTM)0.52
EY18.18%
EPS(NY)0.5
Fwd EY17.48%
FCF(TTM)0.76
FCFY26.41%
OCF(TTM)1.7
OCFY59.31%
SpS16.11
BVpS4.68
TBVpS4.16
PEG (NY)0.27
PEG (5Y)0.26
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.74% | ||
| ROE | 11.16% | ||
| ROCE | 7.23% | ||
| ROIC | 5.61% | ||
| ROICexc | 7.31% | ||
| ROICexgc | 7.65% | ||
| OM | 6.99% | ||
| PM (TTM) | 3.25% | ||
| GM | 83.13% | ||
| FCFM | 4.69% |
ROA(3y)0.85%
ROA(5y)0.34%
ROE(3y)3.39%
ROE(5y)1.18%
ROIC(3y)3.46%
ROIC(5y)2.35%
ROICexc(3y)4.47%
ROICexc(5y)3.03%
ROICexgc(3y)4.72%
ROICexgc(5y)3.22%
ROCE(3y)4.46%
ROCE(5y)3.03%
ROICexcg growth 3Y64.29%
ROICexcg growth 5Y26.18%
ROICexc growth 3Y68.25%
ROICexc growth 5Y27.23%
OM growth 3Y67.11%
OM growth 5Y19.19%
PM growth 3Y148.06%
PM growth 5Y18.19%
GM growth 3Y0.37%
GM growth 5Y0.18%
F-Score7
Asset Turnover0.84
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.96 | ||
| Debt/FCF | 12.94 | ||
| Debt/EBITDA | 4.2 | ||
| Cap/Depr | 88.88% | ||
| Cap/Sales | 5.84% | ||
| Interest Coverage | 2.35 | ||
| Cash Conversion | 77.64% | ||
| Profit Quality | 144.43% | ||
| Current Ratio | 1.79 | ||
| Quick Ratio | 1.75 | ||
| Altman-Z | 1.6 |
F-Score7
WACC4.85%
ROIC/WACC1.16
Cap/Depr(3y)56.34%
Cap/Depr(5y)45.08%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)330.51%
EPS 3Y157.01%
EPS 5Y20.79%
EPS Q2Q%138.17%
EPS Next Y20.73%
EPS Next 2Y12.62%
EPS Next 3Y6.48%
EPS Next 5YN/A
Revenue 1Y (TTM)-0.22%
Revenue growth 3Y3.65%
Revenue growth 5Y2.19%
Sales Q2Q%-3.05%
Revenue Next Year4.55%
Revenue Next 2Y2.95%
Revenue Next 3Y2.8%
Revenue Next 5YN/A
EBIT growth 1Y320.43%
EBIT growth 3Y73.21%
EBIT growth 5Y21.8%
EBIT Next Year131.21%
EBIT Next 3Y31.07%
EBIT Next 5YN/A
FCF growth 1Y-11.25%
FCF growth 3Y-17.96%
FCF growth 5Y7.78%
OCF growth 1Y3.29%
OCF growth 3Y-0.57%
OCF growth 5Y2.97%